Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ).
Hangzhou Tigermed Consulting Co., Ltd. has announced a final cash dividend of RMB 3 per 10 shares for the financial year ending December 31, 2024. The payment date for the dividend is set for July 31, 2025, with further details on shareholder approval and tax implications to be announced, indicating a stable financial performance and potential positive impact on shareholder value.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. operates in the healthcare industry, providing clinical trial services and solutions. The company focuses on supporting pharmaceutical and biotechnology companies in their drug development processes, enhancing their market presence in the clinical research sector.
YTD Price Performance: 7.10%
Average Trading Volume: 65
Technical Sentiment Signal: Hold
Current Market Cap: €5.05B
For a thorough assessment of 3347 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue